-
PROVIDERS
Read more
Browse our latest selection of abstracts, manuscripts, and presentations.
- LIFE SCIENCES
- PATIENTS
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
Content
-
Articles5 things to know when navigating clinical development and regulatory pathways for CDx
Scientific and regulatory leaders from Tempus discuss how Tempus’ platform can enhance clinical development for CDx. -
ArticlesQ&A: Using liquid biopsies to build CDx in pancreatic cancer with Actuate Therapeutics
Dr. Andrew Mazar of Actuate Therapeutics shares his perspective on liquid biopsy as a tool for CDx and drug development in pancreatic cancer. -
VideosAACR GSK Product Theater
The Tempus Spotlight Theater this year was on “Delivering on the Promise of Precision Medicine: Leveraging Diagnostics and Data to Drive Next-Generation Drug Development” and was a fireside chat between Kate Sasser, Chief Scientific Officer at Tempus and Anne-Marie Martin, SVP Global Head in the Experimental Medicine Unit at GSK. -
WebinarsAccelerate clinical trial enrollment and site activation
Learn how TriHealth uses the TIME network to identify trial subjects and rapidly activate new clinical trials within its oncology portfolio within an average of ~10 business days. -
WebinarsTempus’ FDA approval and insights on the use of companion diagnostics in clinical development
Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel. -
Case StudiesUsing TIME to accelerate trial enrollment for Aadi Bioscience
The Tempus TIME program provided Aadi access to a network of providers and patients to accelerate enrollment for its PRECISION 1 TSC1/TSC2 phase 2 clinical trial. Read on to learn how the TIME program decreased time to enroll with the just-in-time activation of ~10 business days. -
Webinars
NGS in advanced breast cancer: exploring recent clinical advancements
Learn more about breast cancer management with NGS. We explore the potential utility of complementary solid tumor and liquid biopsy testing in informing treatment decisions, as well as patient management strategies in the post CDK4/6 inhibitor therapy setting. -
BlogLeveraging Tempus AI and multimodal data to increase probability of technical success in Biopharma
Iker Huerga, SVP of Life Sciences Strategy -
ArticlesUsing multimodal real-world data for decision-making
Learn more about Gilead Sciences’ efforts to drive biomarker innovations and assemble their organization for integrated, data-driven research. -
WebinarsIncreasing PTS using multimodal data
Learn how AstraZeneca employs multimodal data to increase the probability of technical success of all Phase 3 oncology studies. -
ArticlesQ&A: Using RWE for CDx and drug development
Leaders from Kronos Bio discuss how they use RWD from heterogeneous sources to strengthen companion diagnostic and drug development strategies. -
Case StudiesUltra-rapid site activation and subject consent in PARPi Study using Tempus TIME Program
The TIME program enabled activation of a new clinical trial site within 4 business days for a PARPi study. Read on to learn how the patient was able to dose within 10 days of being identified as a match for the trial. -
BlogPrecision medicine made real: enhancing genetic testing with AI algorithms
Martin Stumpe, Chief of AI -
ArticlesQ&A: De-risking clinical trials with real-world data
Iker Huerga, SVP, Life Sciences Strategy and RWD at Tempus, discusses how heterogeneous data sources can strengthen clinical trial planning and execution to de-risk research. -
ArticlesAdvancing immuno-oncology with real-world data
Discover how TScan uses RWD to power companion diagnostic and drug development and ensure the right patients are involved in their clinical studies. -
Case StudiesAccelerate trial enrollment with TIME
Learn how TIME gave Sermonix access to a network of providers and patients to accelerate enrollment in ELAINE II. -
WebinarsMultimodal data drives biomarker innovation
We spoke with Gilead experts to learn how the company uses multimodal data to achieve early successes in translational biomarker research and discovery. -
ArticlesDual testing in metastatic breast cancer
Tempus research exploring the concordance of pathogenic variants across a variety of criteria for metastatic breast cancer patients. -
ArticlesData-driven companion diagnostic development
At the World Clinical Biomarkers and CDx Summit, biopharma leaders shared how they’re using RWD in oncology to drive CDx and therapeutic innovation. -
ArticlesNew research seeks to explain difference in ICB therapy response
Tempus developed an integrative model of tumor-extrinsic and tumor-intrinsic features associated with longer time to progression in NSCLC patients.